inMIND: A Phase 3 Study of Tafasitamab plus Lenalidomide Add-On to Rituximab vs Placebo plus Lenalidomide Add-On to Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)

被引：0
|
作者：
Sehn, Laurie H. [1 ,2 ]
Scholz, Christian W. [3 ]
Luminari, Stefano [4 ]
Salar, Antonio [5 ]
Wahlin, Bjorn E. [6 ]
Gopal, Ajay K. [7 ]
Bonnet, Christophe [8 ]
Trneny, Marek [9 ]
Paneesha, Shankara [10 ]
Manzke, Oliver [11 ]
Seguy, Francis [11 ]
Li, Di [12 ]
Huebel, Kai [13 ]
机构：
[1] BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada
[2] Univ British Columbia, Vancouver, BC, Canada
[3] Vivantes Klinikum Urban, Dept Hematol & Oncol, Berlin, Germany
[4] Azienda USL IRCCS Reggio Emilia, Hematol Unit, Reggio Emilia, Italy
[5] Hosp Mar IMIM, Dept Haematol, Barcelona, Spain
[6] Karolinska Inst, Dept Med, Hematol Unit, Stockholm, Sweden
[7] Univ Washington Med, Div Med Oncol, Seattle, WA USA
[8] Univ Liege, Ctr Hosp Univ, Clin Hematol, Liege, Belgium
[9] Charles Univ Prague, Gen Hosp, Fac Med 1, Dept Med 1, Prague, Czech Republic
[10] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England
[11] Incyte Biosci Int Sarl, Morges, Switzerland
[12] Incyte Corp, Wilmington, DE USA
[13] Univ Hosp Cologne, Dept Internal Med Oncol & Hematol, Cologne, Germany
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷
关键词：
IBCL; non-Hodgkin lymphoma; follicular lymphoma; marginal zone lymphoma; tafasitamab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IBCL-131
引用
收藏
页码：S402 / S402
页数：1
相关论文
共 50 条
  • [1] inMIND: A Phase 3 Study of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)
    Sehn, Laurie H.
    Hubel, Kai
    Luminari, Stefano
    Salar, Antonio
    Wahlin, Bjorn E.
    Gopal, Ajay K.
    Bonnet, Christophe
    Paneesha, Shankara
    Trneny, Marek
    Mashegu, Hafsat
    Lihou, Christine F.
    Cheng, Lulu
    Scholz, Christian W.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S385 - S386
  • [2] A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).
    Sehn, Laurie Helen
    Scholz, Christian W.
    Luminari, Stefano
    Salar, Antonio
    Wahlin, Bjorn E.
    Gopal, Ajay K.
    Bonnet, Christophe Marc
    Paneesha, Shankara
    Manzke, Oliver
    Seguy, Francis
    Li, Di
    Huebel, Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] inMIND: A phase 3 study of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab for relapsed/refractory follicular or marginal zone lymphoma.
    Sehn, Laurie Helen
    Hubel, Kai
    Luminari, Stefano
    Salar, Antonio
    Wahlin, Bjorn E.
    Gopal, Ajay K.
    Bonnet, Christophe Marc
    Paneesha, Shankara
    Trneny, Marek
    Mashegu, Hafsat Umar
    Lihou, Christine Francis
    Li, Di
    Scholz, Christian W.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5).
    Vitolo, Umberto
    Merli, Michele
    Norasetthada, Lalita
    Wassenaar, Timothy Robert
    Martin, Eva Maria Donato
    Bobillo, Sabela
    Shen, Biyi
    Flink, Dina M.
    Zhu, Min
    Chandrasekharan, Soujanya
    Brouwer-Visser, Jurriaan
    Chaudhry, Aafia
    Mohamed, Hesham
    Ambati, Srikanth R.
    Cordoba, Raul
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND)
    Sehn, Laurie H.
    Luminari, Stefano
    Scholz, Christian W.
    Huebel, Kai
    Salar, Antonio
    Paneesha, Shankara
    Wahlin, Bjorn E.
    Panayiotidis, Panayiotis
    Lee, Hui-Peng
    Ubieto, Ana Jimenez
    Sancho, Juan-Manuel
    Kim, Tae Min
    Domenech, Eva Domingo
    Kumode, Takahiro
    Poh, Christina
    Thieblemont, Catherine
    Deeren, Dries
    de Wit, Edwin
    Arbushites, Michael
    Casadebaig, Marie-Laure
    Trneny, Marek
    BLOOD, 2024, 144 : LBA1 - LBA4
  • [6] MAHOGANY: A Phase 3 trial of Zanubrutinib (ZANU) plus anti-CD20 antibodies vs Lenalidomide plus Rituximab (L plus R) in patients (pts) with Relapsed or Refractory (R/R) Follicular or Marginal Zone Lymphoma (FL or MZL)
    Buske, C.
    Nastoupil, L. J.
    Song, Y.
    Sehn, L.
    Sarkozy, C.
    Zinzani, P. L.
    Salar, A.
    Zhang, J.
    Zhang, W.
    Fustier, P.
    Delarue, R.
    Trotman, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 305 - 306
  • [7] MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma
    Andorsky, David J.
    Yacoub, Abdulraheem
    Bitran, Jacob D.
    Melear, Jason
    Brooks, Heather D.
    Foon, Kenneth A.
    Rizvi, Syed
    Llorente, Mary
    Li, Jiahui
    Sharman, Jeff P.
    BLOOD, 2016, 128 (22)
  • [8] CURRENT EPCORITAMAB PLUS RITUXIMAB AND LENALIDOMIDE (R2) PERCEPTIONS FOR PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
    Levine, E.
    Gentile, D.
    Swain, R.
    Bone, R. N.
    Jennings-Zhang, L.
    Jeune-Smith, Y.
    Feinberg, B.
    VALUE IN HEALTH, 2024, 27 (12) : S342 - S342
  • [9] LENALIDOMIDE PLUS RITUXIMAB IN ELDERLY PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
    Della Cioppa, P.
    Lucania, A.
    Esposito, M.
    Improta, S.
    Mastrullo, L.
    HAEMATOLOGICA, 2015, 100 : 151 - 151
  • [10] AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
    Leonard, John P.
    Trneny, Marek
    Izutsu, Koji
    Fowler, Nathan H.
    Hong, Xiaonan
    Zhu, Jun
    Zhang, Huilai
    Offner, Fritz
    Scheliga, Adriana
    Nowakowski, Grzegorz S.
    Pinto, Antonio
    Re, Francesca
    Fogliatto, Laura Maria
    Scheinberg, Phillip
    Flinn, Ian W.
    Moreira, Claudia
    Cabecadas, Jose
    Liu, David
    Kalambakas, Stacey
    Fustier, Pierre
    Wu, Chengqing
    Gribben, John G.
    Calaminici, Maria
    Copie-Bergman, Christiane
    Lopez-Guillermo, Armando
    O'Connor, Owen
    Williams, Michael
    Suciu, Stefan
    Levine, Benjamin
    Kern, Julie
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (14) : 1188 - +
12345